PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)74292-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)74292-3/fulltext
Section Title :
Section Order :
218
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74292-3&doi=10.1016/S1098-3015(10)74292-3